Contineum Therapeutics (CTNM) Competitors $12.32 +0.65 (+5.57%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$12.29 -0.03 (-0.24%) As of 10/15/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. SION, NUVB, ARDX, ZYME, TRML, AMPH, CVAC, TSHA, MAZE, and IMNMShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Sionna Therapeutics (SION), Nuvation Bio (NUVB), Ardelyx (ARDX), Zymeworks (ZYME), Tourmaline Bio (TRML), Amphastar Pharmaceuticals (AMPH), CureVac (CVAC), Taysha Gene Therapies (TSHA), Maze Therapeutics (MAZE), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Its Competitors Sionna Therapeutics Nuvation Bio Ardelyx Zymeworks Tourmaline Bio Amphastar Pharmaceuticals CureVac Taysha Gene Therapies Maze Therapeutics Immunome Sionna Therapeutics (NASDAQ:SION) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Do analysts prefer SION or CTNM? Sionna Therapeutics presently has a consensus target price of $38.00, indicating a potential upside of 22.94%. Contineum Therapeutics has a consensus target price of $22.20, indicating a potential upside of 80.19%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71Contineum Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has better valuation & earnings, SION or CTNM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AContineum TherapeuticsN/AN/A-$42.26M-$2.20-5.60 Is SION or CTNM more profitable? Sionna Therapeutics' return on equity of 0.00% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Contineum Therapeutics N/A -29.75%-28.08% Does the media favor SION or CTNM? In the previous week, Sionna Therapeutics had 8 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Sionna Therapeutics and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.83 beat Sionna Therapeutics' score of 0.47 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryContineum Therapeutics beats Sionna Therapeutics on 6 of the 9 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$327.25M$3.36B$6.11B$10.45BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-5.6022.7785.3627.36Price / SalesN/A486.00596.99137.58Price / CashN/A46.7037.4661.86Price / Book1.6110.5512.286.81Net Income-$42.26M-$52.58M$3.32B$276.80M7 Day Performance1.32%0.09%0.59%0.42%1 Month Performance3.70%15.61%10.54%7.86%1 Year Performance-25.65%15.13%70.62%41.24% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics2.7303 of 5 stars$12.32+5.6%$22.20+80.2%-25.1%$327.25MN/A-5.6031SIONSionna Therapeutics2.5395 of 5 stars$28.40-2.9%$38.00+33.8%N/A$1.25BN/A0.0035News CoverageInsider TradeNUVBNuvation Bio2.8415 of 5 stars$3.63-3.8%$7.86+116.7%+62.0%$1.24B$7.87M-5.7560Analyst ForecastARDXArdelyx4.327 of 5 stars$5.15-1.1%$11.70+127.4%-14.1%$1.24B$333.61M-22.3790Analyst RevisionZYMEZymeworks0.0732 of 5 stars$16.48-1.3%N/AN/A$1.24B$122.87M-16.99460Analyst UpgradeTRMLTourmaline Bio1.5228 of 5 stars$47.90+0.1%$45.65-4.7%+86.0%$1.23BN/A-13.9644AMPHAmphastar Pharmaceuticals4.5944 of 5 stars$26.23-1.3%$31.60+20.5%-53.1%$1.22B$722.68M9.842,028News CoverageCVACCureVac3.8568 of 5 stars$5.41-0.1%$6.83+26.4%+92.2%$1.21B$579.18M5.63880TSHATaysha Gene Therapies2.4162 of 5 stars$4.44+0.3%$9.00+102.9%+173.8%$1.21B$8.10M-13.04180Gap UpMAZEMaze Therapeutics3.1628 of 5 stars$27.44-0.3%$33.83+23.3%N/A$1.20B$167.50M0.00121IMNMImmunome1.614 of 5 stars$13.77-4.5%$23.20+68.5%+34.2%$1.20B$12.59M-4.4640 Related Companies and Tools Related Companies SION Competitors NUVB Competitors ARDX Competitors ZYME Competitors TRML Competitors AMPH Competitors CVAC Competitors TSHA Competitors MAZE Competitors IMNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
